Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KHK4827 (brodalumab) Phase 2 in Plaque Psoriasis
NCT01748539Phase 2Completed
- Sponsor
- Kyowa Kirin
- Start
- Dec 2012
- Primary completion
- Sep 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of brodalumab in plaque psoriasis (4 arms), sponsored by Kyowa Kirin. Primary endpoint: Percent improvement from baseline in Psoriasis Area and Severity Index at 12 weeks. Started Dec 2012; status: completed.
02
Drugs
brodalumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT01748539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01748539.